The FDA on October 13, 2023, approved OPDIVO® for the adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older. OPDIVO® is a product of Bristol-Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement